Mental health experts have welcomed TGA approval of Servier's LATUDA (lurasidone HCl) for the treatment of schizophrenia in adolescents (aged 13-17 years) as “an important therapy” for young patients with what is a debilitating mental illness. …
New Stories
-
One path might be better than the other
June 19, 2018 - - Latest News -
A familiar name returns to lead MSD
June 19, 2018 - - PharmaDispatch Executive -
New studies back Sandoz biosimilars
June 19, 2018 - - Latest News -
MA: SPAs a 'critical element' to ensure access
June 18, 2018 - -
July PBS schedule update
June 18, 2018 - - Latest News -
New appointment for GBMA
June 18, 2018 - - Latest News -
Sirtex accepts $1.9bn takeover bid
June 18, 2018 - - Latest News